Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in primary lung adenocarcinoma Caucasian patients
Open Access
- 6 November 2012
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (3) , 742-748
Abstract
Non-small-cell lung carcinoma (NSCLC) patients with a BRAFV600E mutation benefit from targeted therapy. The usefulness of immunohistochemistry (IHC) as an alternative approach for the detection of BRAFV600E in NSCLC patients has not been evaluated until now. This study compared the specificity and sensitivity of IHC with other methods for the detection of BRAFV600E in primary lung adenocarcinoma. BRAF mutations were analysed by DNA sequencing of a Caucasian subpopulation of selected 450 of 1509 (30%) EGFR, KRAS, PI3KA, Her2 and EML4-ALK wild-type (wt) primary lung adenocarcinomas. Detection of the BRAFV600E mutation was carried out by IHC using the VE1 clone antibody and compared with the results of other molecular methodologies. Of 450 (9%) of tumours, 40 harboured a BRAF mutation, which corresponded to either a BRAFV600E or a non-BRAFV600E mutation in 21 of 450 (5%) and 19 of 450 (4%) cases, respectively. The IHC VE1 assay was positive in 19 of 21 (90%) BRAFV600E-mutated tumours and negative in all BRAFnonV600E-mutated tumours. IHC using the VE1 clone is a specific and sensitive method for the detection of BRAFV600E and may be an alternative to molecular biology for the detection of mutations in NSCLC.Keywords
This publication has 33 references indexed in Scilit:
- Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutationsCancer Letters, 2012
- Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinomaLung Cancer, 2012
- CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor ActivityMolecular Cancer Therapeutics, 2012
- Molecular pathology of lung cancer: key to personalized medicineLaboratory Investigation, 2012
- Role of molecular studies in the diagnosis of lung adenocarcinomaLaboratory Investigation, 2012
- Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinomaAnnals of Oncology, 2011
- Novel Therapeutic Targets in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung CancerClinical Cancer Research, 2010
- Sorafenib Inhibits Non–Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant CellsCancer Research, 2009